Business
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Product theater presentation will be held on May 7 to highlight clinical data and attributes of the first new antifungal class approved in more than 25 years
About this update from Scynexis, Inc.
[{"type":"text","content":"Product theater presentation will be held on May 7 to highlight clinical data and attributes of the first new antifungal class approved in more than 25 years\nJERSEY CITY, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will present new data from its ongoing FURI study of ibrexafungerp during the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting being held in San Diego, May 6-8, 2022. “We are excited to attend this important meeting, which brings together many of the top medical minds in the OB/GYN field,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “We look forward to sharing details about our latest advancements in the area of women’s health.” Poster Presentation: Title: Oral Ibrexafungerp Outcomes in Subjects with Refractory Vulvovaginal Candidiasis from an Open-label Study (FURI)Poster Session BDate/Time: May 6, 2022/1:00 p.m. – 2:00 p.m. PTLocation: San Diego Convention Center, Hall E Poster: A122Presenter: Tosin Goje M.D., MSCR, FACOG Product Theater: Title: A Novel Treatment to Meet the Evolving Challenge of Vulvovaginal CandidiasisDate: Saturday, May 7, 2022 Time: 7:00 a.m. – 7:30 a.m. PTLocation: San Diego Convention Center, Room 6CPresenter: Michael L. Krychman, M.D. For more information, see the ACOG website here. About Ibrexafungerp Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients. It has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) on June 1, 2021. The FDA also granted Qualified Infect...